Integral Health Asset Management LLC Trims Stock Position in Medtronic PLC $MDT

Integral Health Asset Management LLC lessened its stake in Medtronic PLC (NYSE:MDT) by 25.0% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 150,000 shares of the medical technology company’s stock after selling 50,000 shares during the period. Medtronic comprises 1.0% of Integral Health Asset Management LLC’s investment portfolio, making the stock its 29th biggest position. Integral Health Asset Management LLC’s holdings in Medtronic were worth $14,286,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of MDT. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its holdings in Medtronic by 4.2% during the third quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 4,910 shares of the medical technology company’s stock worth $468,000 after acquiring an additional 200 shares during the period. Siemens Fonds Invest GmbH grew its position in Medtronic by 5.8% during the third quarter. Siemens Fonds Invest GmbH now owns 61,941 shares of the medical technology company’s stock valued at $5,899,000 after buying an additional 3,409 shares during the period. Wellington Management Group LLP raised its position in shares of Medtronic by 35.3% in the third quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company’s stock worth $970,456,000 after acquiring an additional 2,658,981 shares during the period. Wayfinding Financial LLC acquired a new stake in shares of Medtronic during the 3rd quarter valued at about $210,000. Finally, Diligent Investors LLC increased its stake in shares of Medtronic by 4.5% in the 3rd quarter. Diligent Investors LLC now owns 9,998 shares of the medical technology company’s stock valued at $952,000 after purchasing an additional 432 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Trading Down 0.4%

Shares of NYSE MDT opened at $87.05 on Friday. The stock has a fifty day simple moving average of $97.96 and a 200-day simple moving average of $96.84. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $111.77 billion, a PE ratio of 24.25, a PEG ratio of 2.24 and a beta of 0.71.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.Medtronic’s revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be paid a $0.71 dividend. The ex-dividend date is Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.3%. Medtronic’s payout ratio is 79.11%.

Analyst Ratings Changes

A number of analysts have recently commented on MDT shares. Barclays restated an “overweight” rating and issued a $118.00 price objective on shares of Medtronic in a research report on Wednesday, February 18th. Citigroup initiated coverage on Medtronic in a research note on Tuesday, February 3rd. They set a “buy” rating and a $117.00 price objective for the company. Wall Street Zen lowered Medtronic from a “buy” rating to a “hold” rating in a research note on Sunday, March 1st. Leerink Partners reaffirmed an “outperform” rating and set a $119.00 target price on shares of Medtronic in a research note on Tuesday. Finally, Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $110.74.

Insider Activity

In other news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.26% of the company’s stock.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).